Glenmark Generics receives final ANDA approval for Eszopiclone Tablets

Glenmark Generics Limited (GGL) aims to be a global integrated Generic and API leader


US FDAfor Eszopiclone Tablets

Glenmark Generics Inc., USA a subsidiary of Glenmark Generics Limited has been granted final abbreviated new drug approval (ANDA) from the United States Food and Drug Administration (US FDA) for Eszopiclone Tablets. Glenmark will commence distribution of the product immediately.

Eszopiclone Tablets are Glenmark's generic version of Sunovion's Lunesta®. Eszopiclone is indicated for the treatment of insomnia. The approval is for the 1mg, 2mg and 3mg tablets. For the 12 month period ending December 2013, Lunesta® garnered annual sales of USD 824 million according to IMS Health.

Glenmark's current portfolio consists of 91 products authorized for distribution in the U.S. marketplace and 63 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.

1 Comment Comment 1 - 1 of 1

Smithd47 22 June 2014 at 03:56 PM

Hello! Do you use Twitter? I'd like to follow you if that would be okay. I'm undoubtedly enjoying your blog and look forward to new posts. kcaaaddkdbdcgbgd


Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email